新型头孢烯抗生素KP-736的体外抗菌活性
In vitro antibacterial activity of KP-736, a new cephem antibiotic.
作者信息
Maejima T, Inoue M, Mitsuhashi S
机构信息
Episome Institute, Gunma, Japan.
出版信息
Antimicrob Agents Chemother. 1991 Jan;35(1):104-10. doi: 10.1128/AAC.35.1.104.
Abstract
KP-736, a new cephen antibiotic with a broad antibacterial spectrum and potent antipseudomonal activity, was evaluated for in vitro antibacterial activity in comparison with ceftazidime, cefotaxime, and cefpirome. KP-736 was significantly more active than the test compounds against gram-negative bacteria, including the Pseudomonas group and ceftazidime-, cefotaxime-, or imipenem-resistant strains, but less active against gram-positive bacteria. KP-736 had very high affinities for penicillin-binding protein 3 (PBP 3) of Escherichia coli K-12 and PBP 1A and PBP 3 of Pseudomonas aerugiosa NCTC 10490 and showed potent bactericidal activities against these two strains. It was stable to hydrolysis by penicillinases and cephalosporinases but was slightly hydrolyzed by oxyiminocephalosporinases and type II penicillinase.
摘要
KP - 736是一种新型头孢菌素抗生素，具有广谱抗菌活性和强大的抗假单胞菌活性。我们将其与头孢他啶、头孢噻肟和头孢匹罗进行比较，评估了它的体外抗菌活性。与测试化合物相比，KP - 736对革兰氏阴性菌具有显著更高的活性，包括假单胞菌属以及对头孢他啶、头孢噻肟或亚胺培南耐药的菌株，但对革兰氏阳性菌的活性较低。KP - 736对大肠杆菌K - 12的青霉素结合蛋白3（PBP 3）以及铜绿假单胞菌NCTC 10490的PBP 1A和PBP 3具有非常高的亲和力，并对这两种菌株显示出强大的杀菌活性。它对青霉素酶和头孢菌素酶的水解稳定，但会被氧亚氨基头孢菌素酶和II型青霉素酶轻微水解。
相似文献
1
In vitro antibacterial activity of KP-736, a new cephem antibiotic.新型头孢烯抗生素KP-736的体外抗菌活性
Antimicrob Agents Chemother. 1991 Jan;35(1):104-10. doi: 10.1128/AAC.35.1.104.
2
In vitro evaluation of E1040, a new cephalosporin with potent antipseudomonal activity.新型具有强效抗假单胞菌活性的头孢菌素E1040的体外评价
Antimicrob Agents Chemother. 1988 May;32(5):693-701. doi: 10.1128/AAC.32.5.693.
3
In vitro antibacterial properties of T-5575 and T-5578 novel parenteral 2-carboxypenams.新型肠胃外给药2-羧基青霉烷类药物T-5575和T-5578的体外抗菌特性
Antimicrob Agents Chemother. 1995 Dec;39(12):2787-91. doi: 10.1128/AAC.39.12.2787.
4
In vitro and in vivo activities of DN-9550, a new broad-spectrum cephalosporin.新型广谱头孢菌素DN-9550的体外和体内活性
Antimicrob Agents Chemother. 1985 Apr;27(4):473-8. doi: 10.1128/AAC.27.4.473.
5
Cefmenoxime (SCE-1365), a novel broad-spectrum cephalosporin: in vitro and in vivo antibacterial activities.头孢甲肟（SCE - 1365），一种新型广谱头孢菌素：体外和体内抗菌活性
Antimicrob Agents Chemother. 1981 Jan;19(1):56-65. doi: 10.1128/AAC.19.1.56.
6
Antibacterial properties of SCE-2787, a new cephem antibiotic.
J Antimicrob Chemother. 1992 May;29(5):509-18. doi: 10.1093/jac/29.5.509.
7
In vitro activity of CP-65,207, a new penem antimicrobial agent, in comparison with those of other agents.新型青霉烯类抗菌剂CP-65,207与其他抗菌剂相比的体外活性。
Antimicrob Agents Chemother. 1989 Aug;33(8):1160-6. doi: 10.1128/AAC.33.8.1160.
8
In vitro activity of LJC10,627, a new carbapenem antibiotic with high stability to dehydropeptidase I.新型碳青霉烯类抗生素LJC10,627对脱氢肽酶I具有高稳定性的体外活性。
Antimicrob Agents Chemother. 1990 Jun;34(6):994-1000. doi: 10.1128/AAC.34.6.994.
9
MEN 10700, a new penem antibiotic: in-vitro activity and its correlation with beta-lactamase stability, PBP affinity and diffusion through the bacterial cell wall.美罗培南10700，一种新型青霉烯类抗生素：体外活性及其与β-内酰胺酶稳定性、青霉素结合蛋白亲和力和通过细菌细胞壁扩散的相关性。
J Antimicrob Chemother. 1998 May;41(5):513-25. doi: 10.1093/jac/41.5.513.
10
The antimicrobial activity of cefpirome, a new cephalosporin.
J Antimicrob Chemother. 1985 Apr;15(4):449-56. doi: 10.1093/jac/15.4.449.
引用本文的文献
1
TonB-Dependent Receptor Repertoire of Pseudomonas aeruginosa for Uptake of Siderophore-Drug Conjugates.铜离子依赖型受体在铜绿假单胞菌摄取铁载体-药物偶联物中的作用。
Antimicrob Agents Chemother. 2018 May 25;62(6). doi: 10.1128/AAC.00097-18. Print 2018 Jun.
2
Antibiotic Hybrids: the Next Generation of Agents and Adjuvants against Gram-Negative Pathogens?抗生素杂合体：下一代针对革兰氏阴性病原体的药物和佐剂？
Clin Microbiol Rev. 2018 Mar 14;31(2). doi: 10.1128/CMR.00077-17. Print 2018 Apr.
3
Structure and Function of the PiuA and PirA Siderophore-Drug Receptors from Pseudomonas aeruginosa and Acinetobacter baumannii.铜绿假单胞菌和鲍曼不动杆菌中PiuA和PirA铁载体-药物受体的结构与功能
Antimicrob Agents Chemother. 2017 Mar 24;61(4). doi: 10.1128/AAC.02531-16. Print 2017 Apr.
4
Penicillin-Binding Protein 3 Is Essential for Growth of Pseudomonas aeruginosa.青霉素结合蛋白3对铜绿假单胞菌的生长至关重要。
Antimicrob Agents Chemother. 2016 Dec 27;61(1). doi: 10.1128/AAC.01651-16. Print 2017 Jan.
5
Involvement of Fe uptake systems and AmpC β-lactamase in susceptibility to the siderophore monosulfactam BAL30072 in Pseudomonas aeruginosa.铜绿假单胞菌中铁摄取系统和 AmpC 型β-内酰胺酶对单肟类铁载体 BAL30072 敏感性的影响。
Antimicrob Agents Chemother. 2013 May;57(5):2095-102. doi: 10.1128/AAC.02474-12. Epub 2013 Feb 19.
6
In vitro and in vivo activities of Syn2190, a novel beta-lactamase inhibitor.新型β-内酰胺酶抑制剂Syn2190的体外和体内活性
Antimicrob Agents Chemother. 1999 Aug;43(8):1895-900. doi: 10.1128/AAC.43.8.1895.
7
Cefpirome. A review of its antibacterial activity, pharmacokinetic properties and clinical efficacy in the treatment of severe nosocomial infections and febrile neutropenia.头孢匹罗。关于其抗菌活性、药代动力学特性及治疗严重医院感染和发热性中性粒细胞减少症临床疗效的综述。
Drugs. 1997 Jul;54(1):117-40. doi: 10.2165/00003495-199754010-00013.
8
Susceptibility to beta-lactam antibiotics of Pseudomonas aeruginosa overproducing penicillin-binding protein 3.高产青霉素结合蛋白3的铜绿假单胞菌对β-内酰胺类抗生素的敏感性
Antimicrob Agents Chemother. 1997 May;41(5):1158-61. doi: 10.1128/AAC.41.5.1158.
9
Cefotaxime. A reappraisal of its antibacterial activity and pharmacokinetic properties, and a review of its therapeutic efficacy when administered twice daily for the treatment of mild to moderate infections.头孢噻肟。对其抗菌活性和药代动力学特性的重新评估，以及对其每日两次给药治疗轻至中度感染时的治疗效果的综述。
Drugs. 1997 Mar;53(3):483-510. doi: 10.2165/00003495-199753030-00009.
10
In vitro and in vivo activities of LB10522, a new catecholic cephalosporin.新型邻苯二酚头孢菌素LB10522的体外和体内活性
Antimicrob Agents Chemother. 1996 Aug;40(8):1825-31. doi: 10.1128/AAC.40.8.1825.
本文引用的文献
1
Comparison of in vitro activity of GR 20263, a novel cephalosporin derivative, with activities of other beta-lactam compounds.新型头孢菌素衍生物GR 20263的体外活性与其他β-内酰胺类化合物活性的比较。
Antimicrob Agents Chemother. 1980 May;17(5):884-9. doi: 10.1128/AAC.17.5.884.
2
Emergence of resistance during therapy with the newer beta-lactam antibiotics: role of inducible beta-lactamases and implications for the future.新型β-内酰胺类抗生素治疗期间耐药性的出现：诱导性β-内酰胺酶的作用及对未来的影响。
Rev Infect Dis. 1983 Jul-Aug;5(4):639-48. doi: 10.1093/clinids/5.4.639.
3
In vitro antimicrobial activity of cefotaxime, a new cephalosporin.新型头孢菌素头孢噻肟的体外抗菌活性
Antimicrob Agents Chemother. 1980 Jul;18(1):1-8. doi: 10.1128/AAC.18.1.1.
4
Emergence of resistance to beta-lactam and aminoglycoside antibiotics during moxalactam therapy of Pseudomonas aeruginosa infections.在使用羟羧氧酰胺菌素治疗铜绿假单胞菌感染期间，对β-内酰胺类和氨基糖苷类抗生素产生耐药性。
Antimicrob Agents Chemother. 1982 Dec;22(6):1037-41. doi: 10.1128/AAC.22.6.1037.
5
In vitro antibacterial activity of E-0702, a new semisynthetic cephalosporin.新型半合成头孢菌素E-0702的体外抗菌活性
Antimicrob Agents Chemother. 1982 Aug;22(2):181-5. doi: 10.1128/AAC.22.2.181.
6
The beta-lactamases of gram-negative bacteria and their possible physiological role.革兰氏阴性菌的β-内酰胺酶及其可能的生理作用。
Adv Microb Physiol. 1973;9:31-88. doi: 10.1016/s0065-2911(08)60376-8.
7
A spectrophotometric assay of beta-lactamase action on penicillins.一种关于β-内酰胺酶对青霉素作用的分光光度测定法。
Biochem J. 1974 Jun;139(3):789-90. doi: 10.1042/bj1390789.
8
Studies on semi-synthetic 7 alpha-formamidocephalosporins. I. Structure-activity relationships in some semi-synthetic 7 alpha-formamidocephalosporins.半合成7α-甲酰胺基头孢菌素的研究。I. 某些半合成7α-甲酰胺基头孢菌素的构效关系。
J Antibiot (Tokyo). 1986 Dec;39(12):1788-91. doi: 10.7164/antibiotics.39.1788.
9
Aminothiazolylglycyl derivatives of carbacephem antibiotics. II. Synthesis and antibacterial activity of novel aminothiazolyl cephem compounds with hydroxypyridone moiety.碳青霉烯抗生素的氨基噻唑基甘氨酰衍生物。II. 含羟基吡啶酮部分的新型氨基噻唑基头孢化合物的合成与抗菌活性
J Antibiot (Tokyo). 1987 Feb;40(2):182-9. doi: 10.7164/antibiotics.40.182.
10
In-vitro antibacterial activity of L-105, a new cephalosporin.新型头孢菌素L-105的体外抗菌活性
J Antimicrob Chemother. 1986 Nov;18(5):585-91. doi: 10.1093/jac/18.5.585.
Zotero 插件